Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2017 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year
Filters applied: . Clear all
Page 1
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer.
Gaschler-Markefski B, Sikken P, Heymach JV, Gottfried M, Mellemgaard A, Novello S, Gann CN, Barrueco J, Reck M, Hanna NH, Kaiser R. Gaschler-Markefski B, et al. Among authors: sikken p. ESMO Open. 2017 Apr 11;2(1):e000102. doi: 10.1136/esmoopen-2016-000102. eCollection 2017. ESMO Open. 2017. PMID: 28761724 Free PMC article.
Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
Hanna NH, Kaiser R, Sullivan RN, Aren OR, Ahn MJ, Tiangco B, Voccia I, Pawel JV, Kovcin V, Agulnik J, Gaschler-Markefski B, Barrueco J, Sikken P, Schloss C, Kim JH; LUME-Lung 2 Study group. Hanna NH, et al. Among authors: sikken p. Lung Cancer. 2016 Dec;102:65-73. doi: 10.1016/j.lungcan.2016.10.011. Epub 2016 Oct 27. Lung Cancer. 2016. PMID: 27987591 Clinical Trial.